drugset / Trial / NCT06773195
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
Phase 1/2
Recruiting
37 enrolled
Memorial Sloan Kettering Cancer Center
BioMed Valley Discoveries, Inc · collabIncyte Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test different doses of ulixertinib to find the highest dose that causes few or mild side effects in participants when given in combination with ruxolitinib.
Timeline
- Start
- 2025-01-07
- Primary completion
- 2028-01
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | — | — |
| Subject | Ulixertinib | Small molecule | 150 mg | — |
| Subject | Ulixertinib | Small molecule | 300 mg | — |
| Subject | Ulixertinib | Small molecule | 450 mg | — |